Tue, June 5, 2012
Mon, June 4, 2012
Sat, June 2, 2012
Fri, June 1, 2012
Thu, May 31, 2012
Wed, May 30, 2012
Tue, May 29, 2012
Mon, May 28, 2012
Sun, May 27, 2012
Sat, May 26, 2012
Fri, May 25, 2012
Thu, May 24, 2012
Wed, May 23, 2012
[ Wed, May 23rd 2012 ]: Market Wire
Moody's Upgrades Mylan

InterMune To Present At The Goldman Sachs 33rd Annual Global Healthcare Conference


  Copy link into your clipboard //health-fitness.news-articles.net/content/2012/ .. hs-33rd-annual-global-healthcare-conference.html
  Print publication without navigation Published in Health and Fitness on by Market Wire


InterMune To Present At The Goldman Sachs 33rd Annual Global Healthcare Conference -- BRISBANE, Calif., May 30, 2012 /PRNewswire/ --

InterMune To Present At The Goldman Sachs 33rd Annual Global Healthcare Conference

[ ]

BRISBANE, Calif., May 30, 2012 /PRNewswire/ -- InterMune, Inc. (NASDAQ: [ ITMN ]) today announced that Daniel G. Welch, Chairman, Chief Executive Officer and President of InterMune, will present at the Goldman Sachs 33rd Annual Global Healthcare Conference at Rancho Palos Verdes, Calif. on Tuesday, June 5 at 10:40 a.m. PDT / 1:40 p.m. EDT.  Mr. Welch will be joined in the presentation by Dr. Jonathan A. Leff, Executive Vice President, Research and Development for InterMune.

To access a live audio webcast of any of the presentation, investors and other interested parties may log on to the investor relations page of InterMune's corporate website at [ www.intermune.com ].  The company recommends logging on to the site 15 minutes prior to the start of the presentation in order to register or download any necessary software.

About InterMune
InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and orphan fibrotic diseases.  In pulmonology, InterMune is focused on therapies for the treatment of idiopathic pulmonary fibrosis (IPF), a progressive and fatal lung disease.  Pirfenidone, the only medicine approved for IPF anywhere in the world, is approved for marketing by InterMune in the EU as Esbriet® and is currently in a Phase 3 clinical trial to support regulatory registration in the United States.  InterMune's research programs are focused on the discovery of targeted, small-molecule therapeutics and biomarkers to treat and monitor serious pulmonary and fibrotic diseases.  For additional information about InterMune and its R&D pipeline, please visit [ www.intermune.com ].

 

SOURCE InterMune, Inc.

[ Back to top ]

RELATED LINKS
[ http://www.intermune.com ]


Publication Contributing Sources

Publication Sponsors
[ Last Sunday ] - Oceanside Rental Gear